Literature DB >> 25412869

(68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer.

Matthias Eiber1, Stephan G Nekolla, Tobias Maurer, Gregor Weirich, Hans-Jürgen Wester, Markus Schwaiger.   

Abstract

Current imaging procedures for prostate cancer including positron emission tomography (PET) exhibit considerable limitations and are not always able to meet the diagnostic needs. Recently, a (68)Gallium-labeled ligand of the prostate-specific membrane antigen ((68)Ga-PSMA) has been introduced in PET-imaging of prostate cancer with first promising results. Due to relatively exclusive expression of PSMA in prostatic tissue as well as increased expression in prostate cancer, 68 Ga-PSMA was reported to exhibit a favorable lesion to background ratio. Together with the novel development of combined PET/MRI, the combination of excellent morphological detail, multiparametric functional information, and molecular PET data might lead to a significant improvement in detection of prostate cancer. We present an exemplarily case of primary staging using multiparametric (68)Ga-PSMA PET/MR by combining molecular and structural information.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25412869     DOI： 10.1007/s00261-014-0301-z

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN： 0942-8925


  36 in total

Review 1.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

Review 2.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

3.  Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI.

Authors:  Ali Afshar-Oromieh; Maya Wolf; Uwe Haberkorn; Marc Kachelrieß; Regula Gnirs; Klaus Kopka; Heinz-Peter Schlemmer; Martin T Freitag
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-15       Impact factor: 9.236

4.  Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [68Ga]Ga-P15-041, a gallium-68 labeled bisphosphonate, from first-in-human studies.

Authors:  Robert K Doot; Anthony J Young; Margaret E Daube-Witherspoon; David Alexoff; Kyle J Labban; Hwan Lee; Zehui Wu; Zhihao Zha; Seok R Choi; Karl H Ploessl; Erin K Schubert; Hsiaoju Lee; Lin Zhu; Janet S Reddin; Joel S Karp; Hank Kung; Daniel A Pryma
Journal:  Nucl Med Biol       Date:  2020-04-20       Impact factor: 2.408

5.  Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.

Authors:  Melanie Hohberg; Wolfgang Eschner; Matthias Schmidt; Markus Dietlein; Carsten Kobe; Thomas Fischer; Alexander Drzezga; Markus Wild
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

6.  Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.

Authors:  Sangeeta Ray Banerjee; Zhengping Chen; Mrudula Pullambhatla; Ala Lisok; Jian Chen; Ronnie C Mease; Martin G Pomper
Journal:  Bioconjug Chem       Date:  2016-05-09       Impact factor: 4.774

7.  [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.

Authors:  Ying Chen; Ala Lisok; Samit Chatterjee; Bryan Wharram; Mrudula Pullambhatla; Yuchuan Wang; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Bioconjug Chem       Date:  2016-06-24       Impact factor: 4.774

Review 8.  Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors:  Hossein Jadvar
Journal:  Abdom Radiol (NY)       Date:  2016-05

9.  MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.

Authors:  Constantinos Zamboglou; Gesche Wieser; Steffen Hennies; Irene Rempel; Simon Kirste; Martin Soschynski; Hans Christian Rischke; Tobias Fechter; Cordula A Jilg; Mathias Langer; Philipp T Meyer; Michael Bock; Anca-Ligia Grosu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

10.  Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.

Authors:  Christian H Pfob; Sibylle Ziegler; Frank Philipp Graner; Markus Köhner; Sylvia Schachoff; Birgit Blechert; Hans-Jürgen Wester; Klemens Scheidhauer; Markus Schwaiger; Tobias Maurer; Matthias Eiber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-20       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.